Tirzepatide is the one drug in this class with a contraceptive warning on its label, and the instruction is specific enough to be worth reading in full rather than summarizing.
What the label actually says
Section 8.3 states that use of the drug may reduce the efficacy of oral hormonal contraceptives due to delayed gastric emptying, and that the delay is largest after the first dose and diminishes over time [1].
The instruction that follows is to switch to a non-oral contraceptive method, or to add a barrier method, for four weeks after initiation and for four weeks after each dose escalation.
Section 7.2 adds the part people most often miss. Hormonal contraceptives that are not administered orally should not be affected.
The same wording appears on the type 2 diabetes label for the same molecule [2]. Which brand is prescribed does not change the advice.
The study behind the instruction
One pharmacokinetic study produced these figures. It gave a combined oral contraceptive containing 0.035 mg ethinyl estradiol and 0.25 mg norgestimate alongside a single 5 mg dose of tirzepatide [1].
| Component | Peak concentration | Total exposure | Time to peak |
|---|---|---|---|
| Ethinyl estradiol | −59% | −20% | Delayed 2.5 to 4.5 hours |
| Norgestimate | −66% | −21% | Delayed 2.5 to 4.5 hours |
| Norelgestromin | −55% | −23% | Delayed 2.5 to 4.5 hours |
The two columns tell different stories, and a 2026 review makes the point directly [4]. A fall in peak concentration cannot be equated with reduced efficacy.
Total exposure fell by about a fifth, which is a much smaller change than the peak figures suggest. The drug arrived later and lower, not in substantially smaller quantity.
That review also notes what has not been studied. No equivalent data exist for oral progestogens used for gynecologic conditions or in menopausal hormone therapy, and results from one formulation do not transfer automatically to a structurally different one.
Why semaglutide has no equivalent warning
A 2024 review compared six trials of incretin drugs against oral hormonal contraceptives [3]. Only the tirzepatide study showed a statistically significant reduction in exposure, peak concentration and time to peak.
The five GLP-1 studies showed no statistically or clinically significant effect. The authors attribute the difference to tirzepatide's rapid dose escalation and its larger effect on stomach emptying.
The labels reflect that. A search of the Wegovy prescribing information finds no occurrence of the word contraceptive at all [5].
The Ozempic label mentions it once, inside a drug-interaction figure covering an ethinylestradiol and levonorgestrel product [6]. Its conclusion is that no clinically relevant interaction was observed and no dose adjustment is required.
Fertility is the other half of the question
Two things move at once here. The label directs that treatment be discontinued when pregnancy is recognized, because the drug may cause fetal harm [1].
At the same time, weight loss on these drugs can restore ovulation in people who were not ovulating reliably. A 2026 clinical review notes higher spontaneous pregnancy rates in women with polycystic ovary syndrome[7].
So contraceptive reliability matters more on this treatment than it did before it, not less. That review suggests non-oral hormonal methods and long-acting reversible contraception as the more dependable options during treatment.
It also records the washout periods that have been proposed before trying to conceive: two to four weeks for short-acting agents, and eight weeks for semaglutide and tirzepatide.
A 2025 review of this drug class in gynecology reaches the same practical place [8]. The pregnancy-specific questions for the other molecule are covered in Ozempic and pregnancy, and the ovulation side in semaglutide for PCOS.
One more route to a missed dose
Absorption is not the only way a swallowed pill fails on this drug. Vomiting or diarrhea soon after taking one can remove it entirely.
The label records vomiting in 8% to 13% of patients by dose and diarrhea in 19% to 23%, against 2% and 8% on placebo [1]. Both are most common around a dose increase, which is the same window the contraceptive advice covers.
The pattern and timing of those symptoms are covered in tirzepatide diarrhea.
What to raise with a prescriber
Ask which method to use during the four-week windows, and confirm whether your current method is an oral one.
Ask what to do at each dose increase, since the window reopens every time. Ask what happens if a pill is vomited.
And if pregnancy is the goal rather than the risk, ask about a washout period before trying. To compare prescribers by monthly cost, see the compounded tirzepatide rankings, and for the rest of this goal, the weight hub.